The anti-tumor activity of Atorvastatin in vivo was further verified in a transgenic mouse model expressing the clinically relevant EGFR T790M/L858R mutation, in which at treatment termination, Atorvastatin-exposed animals presented with approximately 33% decrease in tumor mass (assessed by MRI) as compared to vehicle-treated transgenic mice. This evidence concerns the gene EGFR and neoplasm.